Evidence map›Paper›PMID 31369409›Full record

ReviewCurrent opinion in lipidology2019

Regulation of calcific vascular and valvular disease by nuclear receptors.

Tamer Sallam, Yin Tintut, Linda L Demer

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in lipidology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Roles of Nuclear Receptors in Vascular Calcification.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Tamer SallamDivision of Cardiology, Department of Medicine.
Yin TintutDivision of Cardiology, Department of Medicine.
Linda L DemerDivision of Cardiology, Department of Medicine.
Oklahoma State University Center for Health Sciences · USUniversity of California, Los Angeles · US

Funding

RNA-binding proteins in atherosclerosisR01HL139549 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Tamer Sallam · 2018 to 2026
$3.3M
Long Non-coding RNAs in the Regulation of Adipogenesis and ObesityR01DK118086 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SALLAM, TAMER · 2018 to 2022
$1.9M
Serotonin receptor contribution to inflammation-induced calcific aortic valve diseaseR01HL137647 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEMER, LINDA L., TINTUT, YIN · 2019 to 2022
$1.6M
Mechanisms of intermittent parathyroid hormone effects on calcific aortic diseaseR01HL121019 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEMER, LINDA L., TINTUT, YIN · 2015 to 2018
$1.5M
Does aging transform calcific vasculopathy into a plaque stabilizing process?R21AG061586 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEMER, LINDA L., TINTUT, YIN · 2019 to 2020
$429k
NHLBI NIH HHS R01 HL121019NHLBI NIH HHS R01 HL137647NHLBI NIH HHS R01 HL139549NIA NIH HHS R21 AG061586NIDDK NIH HHS R01 DK118086
6 · The paper itself

Abstract

purpose of reviewThis review addresses recent developments in studies of lipid regulation of calcific disease of arteries and cardiac valves, including the role of nuclear receptors. The role of lipid-soluble signals and their receptors is timely given the recent evidence and concerns that lipid-lowering treatment may increase the rate of progression of coronary artery calcification, which has been long associated with increased cardiovascular risk. Understanding the mechanisms will be important for interpreting such clinical information. RECENT

findingsNew findings support regulation of calcific vascular and valvular disease by nuclear receptors, including the vitamin D receptor, glucocorticoid receptor, nutrient-sensing nuclear receptors (liver X receptor, farnesoid X receptor, and peroxisome proliferator-activated receptors), and sex hormone (estrogen and androgen) receptors. There were two major unexpected findings: first, vitamin D supplementation, which was previously believed to prevent or reduce vascular calcification, showed no cardiovascular benefit in large randomized, controlled trials. Second, both epidemiological studies and coronary intravascular ultrasound studies suggest that treatment with HMG-CoA reductase inhibitors increases progression of coronary artery calcification, raising a question of whether there are mechanically stable and unstable forms of coronary calcification. SUMMARY: For clinical practice and research, these new findings offer new fundamental mechanisms for vascular calcification and provide new cautionary insights for therapeutic avenues.

Indexed as

ArteriesCalcinosisHeart Valve DiseasesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLipid MetabolismLiver X ReceptorsPeroxisome Proliferator-Activated ReceptorsReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearVascular CalcificationHydroxymethylglutaryl-CoA Reductase InhibitorsLiver X ReceptorsPeroxisome Proliferator-Activated ReceptorsReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and Nuclear

Identifiers

PMID31369409
PMCPMC6719701
OpenAlexW2966229790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.